California Cannabis Legislation

This bill, now inactive, would have prevented individuals with financial ties to cannabis from serving on regulatory bodies, potentially limiting industry influence on future policy.

This bill would allow cannabis products to be sold to consumers even if they fail some quality assurance tests, potentially exposing people to unsafe products.

SB6 adds xylazine to California's controlled substances list, impacting public health and drug policy by regulating its possession and distribution.

This bill could fund local programs, potentially increasing safe access points for consumers and patients while supporting cannabis businesses.

This bill creates a state task force to study cannabis issues, potentially leading to future policy changes that could make it easier to access or operate in the market.

Doctors can now study cannabis more easily, potentially leading to new treatments and better patient care.

Online marketplaces like Amazon must now report illegal cannabis sales and can be held liable, making it harder to buy unregulated products.

This bill means more hemp-derived products, like delta-8 THC, will be regulated and available for purchase, but with stricter testing and labeling requirements.

Consumers will pay less for cannabis as the state temporarily suspends a tax increase, making products more affordable.

More state grant money will fund local cannabis equity programs, helping small businesses and patients in underserved communities.

This bill's failure means cannabis workers won't get easier access to workers' compensation for job-related injuries.

Californians won't see new low-dose hemp drinks in stores, limiting consumer choice for milder cannabis options.

Patients could have received medical cannabis deliveries from licensed retailers statewide, regardless of local bans.